Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Sedanur K GülsaranMehmet BaysalUfuk DemirciVolkan BaşHakkı O KirkizlarElif Gülsüm ÜmitAhmet M DemirPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)
Although the use of ibrutinib is generally well tolerated, cardiac functions should be monitored occasionally in all patients.